Home » Stocks » AYLA

Ayala Pharmaceuticals, Inc. (AYLA)

Stock Price: $9.95 USD -0.05 (-0.50%)
Updated May 13, 2021 9:36 AM EDT - Market closed
After-hours: $9.86 -0.09 (-0.91%) May 13, 4:00 PM
Market Cap 135.72M
Revenue (ttm) 3.71M
Net Income (ttm) -30.15M
Shares Out 13.24M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $9.95
Previous Close $10.00
Change ($) -0.05
Change (%) -0.50%
Day's Open 10.00
Day's Range 9.80 - 10.25
Day's Volume 10,446
52-Week Range 8.62 - 28.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...

3 weeks ago - GlobeNewsWire

- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023

1 month ago - GlobeNewsWire

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) will raise $25 million via a private placement of around 1.7 million units at $15 per unit from institutional investors, including Redmile Group and SIO Capital ...

2 months ago - Benzinga

Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023

2 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...

3 months ago - GlobeNewsWire

Ayala Pharmaceuticals (AYLA) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...

4 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...

4 months ago - GlobeNewsWire

- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study -

4 months ago - GlobeNewsWire

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a c...

5 months ago - Insider Monkey

- Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 -

5 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...

6 months ago - GlobeNewsWire

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs ...

Other stocks mentioned: FUBO, GAN, INTZ, KC, KRON, SPRB, STTK
6 months ago - Seeking Alpha

– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate

7 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small m...

7 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small m...

8 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (the Company or Ayala), a clinical-stage oncology company focused on developing and c...

8 months ago - GlobeNewsWire

– New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 –

9 months ago - GlobeNewsWire

REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mo...

9 months ago - GlobeNewsWire

– Completed upsized initial public offering raising a total of $59.1 million in gross proceeds

10 months ago - GlobeNewsWire

The Phase 2 study of Ayala Pharmaceuticals Inc’s (NASDAQ: AYLA) AL101 candidate is scheduled to begin in the back half of this year.

11 months ago - Benzinga

About AYLA

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small mole... [Read more...]

Industry
Biotechnology
IPO Date
May 8, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AYLA
Full Company Profile

Financial Performance

In 2020, AYLA's revenue was $3.71 million, an increase of 58.87% compared to the previous year's $2.33 million. Losses were -$30.15 million, 69.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for AYLA stock is "Buy." The 12-month stock price forecast is 22.70, which is an increase of 128.14% from the latest price.

Price Target
$22.70
(128.14% upside)
Analyst Consensus: Buy